Chroma Medicine, Nvelop merge

Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio. nChroma will develop Chroma’s epigenetic editing platform and Nvelop’s viruslike delivery platform. The new firm has raised $75 million and says that those funds, along with funding from both predecessor companies, will finance multiple years of operation. nChroma’s lead drug candidate—CRMA-1001, for chronic hepatitis B and D coinfection—has not yet reached clinical trials.

Authors

Publication Details

Journal
C&EN Global Enterprise
Published
2024-12-20
DOI
https://doi.org/10.1021/cen-10239-buscon17
Primary Topic
Delphi Technique in Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Chroma Medicine, Nvelop merge

Sarah Braner
C&EN Global Enterprise
Delphi Technique in Research
article

Chroma Medicine, Nvelop merge

Sarah Braner
article en

Abstract

Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio. nChroma will develop Chroma’s epigenetic editing platform and Nvelop’s viruslike delivery platform. The new firm has raised $75 million and says that those funds, along with funding from both predecessor companies, will finance multiple years of operation. nChroma’s lead drug candidate—CRMA-1001, for chronic hepatitis B and D coinfection—has not yet reached clinical trials.

C&EN Global EnterpriseVol. 102(39)
Openalex Percentile: Top 61%
Delphi Technique in Research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Chroma Medicine, Nvelop merge — Sarah Braner · C&EN Global Enterprise (2024) | TGRS Research Map | TGRS